Flutemetamol F 18

Drug Profile

Flutemetamol F 18

Alternative Names: 18-F Flutemetamol; [18F]flutemetamol; AH-110690; F-18 PiB; F18 flutemetamol; Flutemetamol F18; Flutemetamol F18 Injection; GE 067; Pittsburgh compound B; Vizamyl

Latest Information Update: 27 Jun 2016

Price : $50

At a glance

  • Originator University of Pittsburgh
  • Developer GE Healthcare; University of Pittsburgh
  • Class Aniline compounds; Imaging agents; Small molecules; Thiazoles
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease

Most Recent Events

  • 01 Sep 2014 Registered for Diagnostic imaging in European Union (IV)
  • 01 Sep 2014 Registered for Alzheimer's disease (Diagnosis) in European Union (IV)
  • 16 Jul 2014 Efficacy data from two phase III trials in Alzheimer's disease (diagnosis) presented at the Alzheimer's Association International Conference in July 2014 (AAIC-2014) by GE Healthcare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top